Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: Results from Berlin-Frankfurt-Münster Trial NHL-BFM 95

Journal of Clinical Oncology

Volumn 23, Issue 33, 2005, Pages 8414-8421

  Seidemann, Kathrin ^a   Zimmermann, Martin ^b   Book, Marion ^b   Meyer, Ulrike ^b   Burkhardt, Birgit ^b   Welte, Karl ^b   Reiter, Alfred ^b   Stanulla, Martin ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FOLINIC ACID; LACTATE DEHYDROGENASE; LYMPHOTOXIN; METHOTREXATE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GERMANY; HAPLOTYPE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADOLESCENT; AUSTRIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL; SWITZERLAND;

ADOLESCENT; AUSTRIA; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HAPLOTYPES; HUMANS; LYMPHOMA, NON-HODGKIN; LYMPHOTOXIN-ALPHA; MALE; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; SWITZERLAND; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644667528     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.2179     Document Type: Article

References (49)

1. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104:487-501, 2001
2. Chan FK-M, Siegel RM, Lenardo MJ: Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 13:419-422, 2000
3. Ruuls SR, Sedgwick JD: Unlinking tumor necrosis factor biology from the major histocompatibility complex: Lessons from human genetics and animal models. Am J Hum Genet 65:294-301, 1999
4. Nedwin GE, Naylor SL, Sakaguchi AY, et al: Human lymphotoxin and tumor necrosis factor genes: Structure, homology and chromosome localization. Nucleic Acids Res 13:6361-6373, 1985
5. Spies T, Morton CC, Nedospasov SA, et at: Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex. Proc Natl Acad Sci U S A 83:8699-8702, 1986
6. McGuire W, Hill AVS, Allsopp CEM, et al: Variation in the TNF alpha promoter region associated with susceptibility to cerebral malaria. Nature 371:508-511, 1994
7. Herrmann S-M, Ricard S, Nicaud V, et al: Polymorphisms of the tumor necrosis factor alpha gene, coronary heart disease and obesity Eur J Clin Invest 28:59-66, 1998
8. Knight JC, Udalova I, Hill AVS, et al: A polymorphism that effects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet 22:145-150, 1999
9. Wilson AG, di Giovme FS, Blakemore AIF, et al: Single base polymorphism in the tumor necrosis factor alpha (TNF alphal gene detectable by Ncol restriction of PCR product. Hum Mol Genet 1:353-357, 1992
10. Wilson AG, Symons JA, McDowell TL, et al: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 94:3195-3199, 1997
11. Demeter J, Porzsolt F, Ramisch S, et al: Polymorphisms of the tumor-necrosis factor alpha and lymphotoxin-alpha genes in chronic lymphocytic leukemia. Br J Haematol 97:107-112, 1997
12. Wihlborg C, Sjoberg J, Intaglietta M, et al: Tumor-necrosis factor-alpha cytokine promoter gene polymorphism in Hodgkin's disease and chronic lymphocytic leukaemia. Br J Haematol 104:346-349, 1999
13. Wilson AG, di Giovme FS, Duff GW: Genetics of tumor necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases. J Inflamm 45:1-12, 1995
14. Nadel S, Newport MJ, Booy R, et al: Variation in the tumor necrosis factor alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 174:878-880, 1996
15. Mira J-P, Cariou A, Grail F, et al: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality. JAMA 282:561-568, 1999
16. Cabrera M, Shaw M-A, Sharples C, et al: Polymorphisms in tumor necrosis factor genes associated with mucocutaneous Leishmaniosis. J Exp Med 182:1259-1264, 1995
17. Stüber F, Petersen M, Bokelmann F, et al: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 24:381-384, 1996
18. Messer G, Spengler U, Jung MC, et al: Polymorphic structure of the tumor necrosis factor (TNF) locus: An Ncol polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 173:209-219, 1991
19. Koss K, Satsangi J, Fanning GC, et al: Cytokine (TNF-alpha, LT-alpha, and IL-10) polymorphisms in inflammatory bowel disease and normal controls: Differential effects on production and allele frequencies. Genes Immun 1:185-190, 2000
20. Mulcahy B, Waldron-Lynch F, McDermott MF, et al: Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am J Hum Genet 59:676-683, 1996
21. Mainou-Fowler T, Dickinson AM, Taylor PRA, et al: Tumor necrosis factor gene polymorphisms in lymphoproliferative disease. Leuk Lymphoma 38:547-552, 2000
22. Warzocha K, Salles G, Bienvenu J, et al: The tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol 15:499-508, 1997
23. Warzocha K, Ribeiro P, Bienvenu J, et al: Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91:3574-3581, 1998
24. Warzocha K, Bienvenu J, Ribeiro P, et al: Plasma levels of tumor necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer 77:2357-2362, 1998
25. Davies FE, Rollinson SJ, Rawstron AC, et al: High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have improved progression-free survival after treatment. J Clin Oncol 18:2843-2851, 2000
26. Zheng C, Huang D, Bergenbrant S, et al: Interleukin 6, tumor necrosis factor alpha, interleukin 1 beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 109:39-45, 2000
27. Stanulla M, Schrauder A, Welte K, et al: Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study of patients treated with BFM therapy. BMC Blood Disord 1:2, 2001
28. Harris NL: Principles of the revised European-American Lymphoma Classification (from the International Lymphoma Study Group). Ann Oncol 8:11-16, 1997
29. Stansfeld AG, Diebold J, Kapanci Y, et al: Updated Kiel classification for lymphomas. Lancet 1:292-293, 1988
30. Bennett JM, Catorsky D, Daniel MT, et al: Proposal for the classification of the acute leukemias: French-American-British (FAB) Cooperative Groups. Br J Haematol 33:451-458, 1976
31. Harris NL, Jaffe ES, Stein H, et al: A revised European-American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
32. Reiter A, Schrappe M, Ludwig W-D, et al: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM Group report. Blood 95:416-421, 2000
33. Woessmann W, Seidemann K, Mann G, et al: The impact of methotrexate administration schedule and dose in the therapy of children and adolescents with B-cell neoplasms: A report of the BFM study NHL-BFM 95. Blood 105:948-958, 2005
34. Stanulla M, Schrappe M, Brechlin AM, et al: Polymorphisms within glutathione S-tranferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study. Blood 95:1222-1228, 2000
35. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
36. Greenwood M: A report on the natural duration of cancer. Reports on Public Health and Medical Subjects, 1926, pp 1-26
37. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
38. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
39. Reiter A, Schrappe M, Parwaresch R, etal: Non-Hodgkin's lymphomas of childhood and adolescence: Results of a treatment stratified for biologic subtypes and stage-A report of the Berlin-Frankfurt-Münster Group. J Clin Oncol 13:359-372, 1995
40. Patte C, Auperin A, Michon J, et al: The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370-3379, 2001
41. Kaatsch P, Spix C, Michaelis J: 20 years German Childhood Cancer Registry: Annual Report 1999. Mainz, Germany, Druckbetrieb Lindner OHG, 2000
42. Tsukasaki K, Miller CW, Kubota T, et al: Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type I carriers. Cancer Res 61:3770-3774, 2001
43. Takeuchi S, Takeuchi N, Tsukasaki K, et al: Genetic polymorphisms in the tumor necrosis factor locus in childhood lymphoblastic leukemia. Br J Haematol 119:985-987, 2002
44. Neben K, Mytilineos M, Moehler TM, et al: Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 100:2263-2265, 2002
45. Fitzgibbon J, Grenzelias D, Matthews J, et al: Tumour necrosis factor polymorphisms and susceptibility to follicularlymphoma. Br J Haematol 107:388-391, 1999
46. Ross ME, Caliguri MA: Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 89:910-916, 1997
47. Zheng L, Fisher G, Miller RE, et al: Induction of apoptosis in mature T-cells by tumor necrosis factor. Nature 377, 1995
48. Kobayashi D, Watanabe N, Yamauchi N, et al: Endogenous tumor necrosis factor as a predictor of doxorubicin sensitivity in leukemic patients. Blood 89:2472-2475, 1997
49. Carroll MC, Katzman P, Alicot EM, et al: Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc Natl Acad Sci U S A 84:8535-8539, 1987